title: [Photodynamic therapy of early squamous epithelial carcinomas and severe squamous epithelial dysplasias of the esophagus with 5-aminolevulinic acid].
abstract: BACKGROUND
  Photodynamic therapy (PDT) is a new local, endoscopically controlled therapeutic concept based on the selective sensitization of malignant and precancerous lesions prior to light-induced tissue destruction. 5-aminolaevulinic acid (5-ALA) appears to be a promising alternative photosensitizer with a high mucosa specificity without phototoxic side effects on the skin. We report on our experience with this new form of PDT in 24 patients.
  
  
  METHODS
  Five females and 19 males (aged 50 to 79 years) with histologically proven high-grade dysplasia (n = 9) and early cancer (normal EUS or uTlNOMO, n = 15) of the esophagus were included in this study. Four to six hours after oral ingestion of 5-ALA (dosage of 60 mg/kg b.w.) laser light irradiation was conducted with a dye laser system (XP 800 KTP/YAG, Laserscope, San José, USA) at a wavelength of 635 nm. With a light dose of 150 J/cm2.
  
  
  RESULTS
  The length of the segment with severe dysplasia or mucosal cancer varied between 0.5 and 9 cm (mean length: 3.6 cm). High-grade dysplasia was eradicated in all patients (9/9). In addition, 16 mucosal carcinomas in 15 patients were successfully treated in 8/16 cases with an average of 1.8 treatment sessions and a mean follow-up of 14.5 months (range: 3-31 months). A method-related mortality and morbidity was not observed.
  
  
  CONCLUSIONS
  Severe dysplasia and superficial (< or = 2 mm) mucosal cancer of the esophagus can be completely ablated by 5-ALA-PDT. Patients with early carcinoma thicker than 2 mm are not suitable for 5-ALA-PDT. PDT with 5-ALA has few side effects and might offer an alternative to esophagectomy or radio-chemotherapy.
authors.affiliation: Landeshauptstadt Wiesbaden.
authors.forename: L
authors.initials: L
authors.lastname: Gossner
authors.forename: M
authors.initials: M
authors.lastname: Stolte
authors.forename: R
authors.initials: R
authors.lastname: Sroka
authors.forename: A
authors.initials: A
authors.lastname: May
authors.forename: E G
authors.initials: EG
authors.lastname: Hahn
authors.forename: C
authors.initials: C
authors.lastname: Ell
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010778:Photochemotherapy; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000622:Aminolevulinic Acid
vernacular_title: Photodynamische Therapie von Plattenepithelfrühkarzinomen und schweren plattenepithelialen Dysplasien der Speiseröhre mit 5-Aminolaevulinsäure.